Drug Trial Radar · NCT04887532
A Trial of HR19042 Capsule in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Sep 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jul 1, 2021
Primary completion
Jul 27, 2021
Study completion Jul 27, 2021
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects. To explore the pharmacokinetic characteristics and safety of HR19042 capsule in healthy Chinese subjects.
Conditions
- Primary IgA Nephropathy
Interventions
HR19042 capsuleDrug
phase 1 :8mg; phase 2:12mg; phase 3:16mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 0-24 hours
- AUC0-t;Time frame: 0-24 hours
- AUC0-∞Time frame: 0 hour to 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.